Event Data
{"article_title":"Impact of empagliflozin on cardiac structure and function assessed by echocardiography after myocardial infarction: a post-hoc sub-analysis of the emmy trial.","author":"\"Schwegel, Nora , Strohhofer, Christoph , Kolesnik, Ewald , Oltean, Sabrina , H\u00fcttmair, Alexander , Pipp, Christian , Benedikt, Martin , Verheyen, Nicolas , Gollmer, Johannes , Ablasser, Klemens , Wallner, Markus , Santner, Viktoria , Tripolt, Norbert , Pferschy, Peter , Zechner, Peter , Alber, Hannes , Siller-Matula, Jolanta M , Kopp, Kristen , Zirlik, Andreas , Aziz, Faisal , Sourij, Harald , von Lewinski, Dirk\"","journal_title":"Clinical research in cardiology : official journal of the German Cardiac Society","issn":"1861-0692 ; Electronic","isbn":"","publication_date":"20250501","volume":"114","issue":"5","first_page":"629","page_count":"11","accession_number":"39297940","doi":"10.1007\/s00392-024-02523-1","publisher":"Springer Medizin","doctype":"Clinical Trial, Phase III; Journal Article","subjects":"Cardiology ","interest_area":["Cardiology"," Emergency Medicine"],"abstract":"Declarations. Conflict of interest: HS is on the advisory board and speakers bureau of Boehringer Ingelheim, NovoNordisk, Sanofi-Aventis, Amgen, AstraZeneca, Bayer, Eli Lilly, Kapsch, MSD, and Daiichi Sankyo. DvL is on the advisory board and speaker\u2019s bureau of by Boehringer Ingelheim, Novartis, Sanova, Sanofi, Orion, AstraZeneca, Bayer Recardio, Vaxxinity and Daiichi Sankyo. NS and EK report no conflict of interest related to this study. All other authors report no conflict of interest related to this study. Ethics approval and consent to participate: The EMMY trial was approved by the Ethics committee of the Medical University of Graz, Austria (EK 29\u2013179 ex16\/17, EudraCT 2016\u2013004591-22) and registered at ClinicalTrials.gov (NCT03087773). The trial conformed to the 1964 Declaration of Helsinki and adhered to the guidelines of Good Clinical Practice (ICH GCP E6). All study participants provided written consent. Consent for publication: All authors consent for the publication of this study.","url":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&db=mdl&AN=39297940&authtype=shib&custid=ns346513","isPdfLink":true,"isSAML":false,"additionalInfo":{"Authored_By":"Schwegel N, Strohhofer C, Kolesnik E, Oltean S, H\u00fcttmair A, Pipp C, Benedikt M, Verheyen N, Gollmer J, Ablasser K, Wallner M, Santner V, Tripolt N, Pferschy P, Zechner P, Alber H, Siller-Matula JM, Kopp K, Zirlik A, Aziz F, Sourij H, von Lewinski D","Journal_Info":"Publisher: Springer Medizin Country of Publication: Germany NLM ID: 101264123 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1861-0692 (Electronic) Linking ISSN: 18610684 NLM ISO Abbreviation: Clin Res Cardiol Subsets: MEDLINE","Publication_Type":"Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial","Published_Date":"2025-05-01","Source":"Clinical research in cardiology : official journal of the German Cardiac Society [Clin Res Cardiol] 2025 May; Vol. 114 (5), pp. 629-639. Date of Electronic Publication: 2024 Sep 16.","Languages":"English","Electronic_ISSN":"1861-0692","MeSH_Terms":"Benzhydryl Compounds*\/therapeutic use , Benzhydryl Compounds*\/administration & dosage , Glucosides*\/therapeutic use , Glucosides*\/administration & dosage , Heart Ventricles*\/diagnostic imaging , Heart Ventricles*\/physiopathology , Heart Ventricles*\/drug effects , Myocardial Infarction*\/drug therapy , Myocardial Infarction*\/physiopathology , Myocardial Infarction*\/diagnosis , Sodium-Glucose Transporter 2 Inhibitors*\/therapeutic use , Sodium-Glucose Transporter 2 Inhibitors*\/administration & dosage , Stroke Volume*\/drug effects , Ventricular Function, Left*\/drug effects , Ventricular Function, Left*\/physiology, Aged ; Female ; Humans ; Male ; Middle Aged ; Double-Blind Method ; Echocardiography, Doppler\/methods ; Treatment Outcome","Subjects":"Aged, Female, Humans, Male, Middle Aged, Double-Blind Method, Echocardiography, Doppler methods, Treatment Outcome, Benzhydryl Compounds therapeutic use, Benzhydryl Compounds administration & dosage, Glucosides therapeutic use, Glucosides administration & dosage, Heart Ventricles diagnostic imaging, Heart Ventricles physiopathology, Heart Ventricles drug effects, Myocardial Infarction drug therapy, Myocardial Infarction physiopathology, Myocardial Infarction diagnosis, Sodium-Glucose Transporter 2 Inhibitors therapeutic use, Sodium-Glucose Transporter 2 Inhibitors administration & dosage, Stroke Volume drug effects, Ventricular Function, Left drug effects, Ventricular Function, Left physiology","Title_Abbreviations":"Clinical research in cardiology : official journal of the German Cardiac Society","Volume":"114"},"header":{"DbId":"mdl","DbLabel":"MEDLINE Ultimate","An":"39297940","RelevancyScore":"965","PubType":"Academic Journal","PubTypeId":"academicJournal","PreciseRelevancyScore":"964.780700683594"},"plink":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&site=eds-live&db=mdl&AN=39297940&authtype=shib&custid=ns346513&group=main&profile=eds","upload_link":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&site=eds-live&db=mdl&AN=39297940&authtype=shib&custid=ns346513&group=main&profile=eds"}
Additional Info
["Schwegel N, Strohhofer C, Kolesnik E, Oltean S, H\u00fcttmair A, Pipp C, Benedikt M, Verheyen N, Gollmer J, Ablasser K, Wallner M, Santner V, Tripolt N, Pferschy P, Zechner P, Alber H, Siller-Matula JM, Kopp K, Zirlik A, Aziz F, Sourij H, von Lewinski D","Publisher: Springer Medizin Country of Publication: Germany NLM ID: 101264123 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1861-0692 (Electronic) Linking ISSN: 18610684 NLM ISO Abbreviation: Clin Res Cardiol Subsets: MEDLINE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial","2025-05-01","Clinical research in cardiology : official journal of the German Cardiac Society [Clin Res Cardiol] 2025 May; Vol. 114 (5), pp. 629-639. Date of Electronic Publication: 2024 Sep 16.","English","1861-0692","Benzhydryl Compounds*\/therapeutic use , Benzhydryl Compounds*\/administration & dosage , Glucosides*\/therapeutic use , Glucosides*\/administration & dosage , Heart Ventricles*\/diagnostic imaging , Heart Ventricles*\/physiopathology , Heart Ventricles*\/drug effects , Myocardial Infarction*\/drug therapy , Myocardial Infarction*\/physiopathology , Myocardial Infarction*\/diagnosis , Sodium-Glucose Transporter 2 Inhibitors*\/therapeutic use , Sodium-Glucose Transporter 2 Inhibitors*\/administration & dosage , Stroke Volume*\/drug effects , Ventricular Function, Left*\/drug effects , Ventricular Function, Left*\/physiology, Aged ; Female ; Humans ; Male ; Middle Aged ; Double-Blind Method ; Echocardiography, Doppler\/methods ; Treatment Outcome","Aged, Female, Humans, Male, Middle Aged, Double-Blind Method, Echocardiography, Doppler methods, Treatment Outcome, Benzhydryl Compounds therapeutic use, Benzhydryl Compounds administration & dosage, Glucosides therapeutic use, Glucosides administration & dosage, Heart Ventricles diagnostic imaging, Heart Ventricles physiopathology, Heart Ventricles drug effects, Myocardial Infarction drug therapy, Myocardial Infarction physiopathology, Myocardial Infarction diagnosis, Sodium-Glucose Transporter 2 Inhibitors therapeutic use, Sodium-Glucose Transporter 2 Inhibitors administration & dosage, Stroke Volume drug effects, Ventricular Function, Left drug effects, Ventricular Function, Left physiology","Clinical research in cardiology : official journal of the German Cardiac Society","114"]
Description
Background: Empagliflozin administered after acute myocardial infarction proofed to improve cardiometabolic parameters and biomarkers, but the impact on cardiac function is still largely unknown. The aim of this post-hoc echocardiographic sub-analysis of the EMMY trial was to provide in-depth echocardiographic analysis on the effects of empagliflozin versus placebo on standard and novel echocardiographic structural and functional parameters after acute myocardial infarction.<br />Methods: In this post-hoc analysis of the EMMY trial a subset of 313 patients (157 empagliflozin vs. 156 placebo) was enrolled for post-processing analysis of echocardiographic structural and functional parameters. On top of two-dimensional and Doppler parameters, myocardial deformation analyses were performed to assess ventricular and atrial strain values.<br />Results: Left ventricular volumes showed significant differences in favor of empagliflozin over the course of the trial (change in left ventricular end-diastolic volume median [interquartile range] 8 [-3;19]% versus 13 [0;29]%, p = 0.048; left ventricular end-systolic volume -3 [-15;12]% versus 4 [-12;18]%, p = 0.044). This effect persisted after adjusting for baseline values, age, and sex. Left ventricular systolic and diastolic function overall improved over the course of the trial and parameters for diastolic function showed a distinct trend between groups but did not meet statistical significance in this cohort.<br />Conclusion: In this post-hoc analysis among patients with acute myocardial infarction, treatment with empagliflozin resulted in a significant beneficial effect on left ventricular end-diastolic and end-systolic volume, without significantly improving left ventricular or right ventricular functional parameters compared to placebo after 26 weeks.<br />Gov Registration: NCT03087773.<br /> (© 2024. The Author(s).)
